Background: There have long been concerns that calcium channel blockers (CCBs), widely used to treat hypertension, may contribute to malignant growth through the evasion of apoptosis and proliferation of cancer cells. Worryingly, a recent cohort study found breast cancer patients who used CCBs had higher death rates, but interpreting these results was difficult as they were based on all-cause mortality and medication use before cancer diagnosis. We used UK population-based data to more robustly investigate the association between CCB use and cancer-specific mortality. Methods: We selected a cohort of patients with breast cancer diagnosed between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used adjusted, time-dependent Cox regression models to calculate hazard ratios (HRs) comparing breast cancer-specific and all-cause mortality between postdiagnostic CCB users and nonusers. Results: Our cohort included 23,669 breast cancer patients, of whom 5,141 used CCBs and 3,053 died due to their breast cancer during follow-up. After adjustment, CCB users had similar breast cancerspecific mortality to nonusers (HR = 0.98, 95% confidence interval [CI] = 0.88, 1.08). There was no evidence of a dose-response relationship. We found similar associations for specific CCBs, and for all-cause mortality.
B
reast cancer is the second most common cancer in the world, with 1.7 million new cases diagnosed annually. 1, 2 Around 15% of patients die due to the disease within 5 years, 3 and they suffer markedly reduced quality of life, and substantially higher healthcare costs during treatment and recovery. [4] [5] [6] [7] Calcium channel blockers (CCBs) are a group of antihypertensive medications used to treat cardiovascular diseases such as hypertension and angina. In England, CCBs are recommended as the first-line treatment for hypertension, with around 40 million prescriptions dispensed annually. 8, 9 CCBs are also commonly used in the United States, with 6.5% of adults reporting using them within the past 30 days. 10 Despite their widespread use, there have long been concerns that CCBs may contribute to malignant growth through the evasion of apoptosis and proliferation of cancer cells. [11] [12] [13] In vitro and animal models have shown that CCBs reduce intracellular resting calcium concentration and inhibit apoptotic gene expression. 14, 15 In humans, several studies have investigated the association between CCB use and breast cancer risk. 16 Although they have reached inconsistent conclusions, a recent metaanalysis concluded that long-term CCB use is associated with an increase of 71% (95% confidence interval [CI] = 1, 142) in breast cancer risk when compared with nonusers. 16 The impact of CCB use on breast cancer progression has received much less attention. One study found a 22% increase in mortality among breast cancer patients who used CCBs when compared with nonusers, 17 but these findings are difficult to interpret because the study did not identify cancer-specific deaths, adjust for comorbidities, test for a dose-response relationship, or assess CCB use after diagnosis. Consequently, we used population-based data from the United Kingdom to more robustly assess the association between CCB use and mortality among breast cancer patients. 
METHODS

Data Sources
Our study used data from the UK Clinical Practice Research Datalink (CPRD), linked to deprivation indices from census information, English cancer registry data from the National Cancer Data Repository (NCDR), and death registration data from the Office for National Statistics (ONS). The CPRD contains computerized medical records from 674 general practices (approximately 7% of the UK population) which are audited for data completeness and quality. 18 Practices meeting a predefined quality standard are deemed "up to standard" and included in future extracts. Data recorded includes patient demographics, clinical diagnoses (using Read codes), and prescription medication use. Previous research has found CPRD prescription and clinical information to be of high quality. [18] [19] [20] The NCDR holds UK-wide data from English cancer registries compiled from a variety of sources including general practices, cancer screening programmes, NHS and private hospitals, and death certificates. 21 ONS death registration data provide details on the date and cause(s) of death. Ethical approval for all purely observational research using anonymized Clinical Practice Research Datalink data was obtained from a National Research Ethics Service Committee.
Study Design and Population
We used the NCDR to identify a cohort of female patients with newly diagnosed breast cancer (International Classification of Diseases code C50) between 1998 and 2012. Cohort members with a previous record of cancer were identified and excluded from the analysis using a list of cancer Read codes modified for use in the CPRD. 22 Patients were excluded if they were diagnosed before they were registered with a CPRD practice, before their practice was deemed up to research standard, after they left a CPRD practice, or after data were last collected from their practice by the CPRD. A small number of patients were recorded within the NCDR more than once, when this occurred we used their first record. Patients with stage 0 breast cancer (ductal carcinoma in situ) were also excluded.
Deaths were identified from ONS records, and breast cancer-specific deaths were defined as those with a primary cause of breast cancer (ICD code C50). Patients who died within the first year of the study were excluded as it is unlikely that these could be influenced by postdiagnostic medication use; therefore, the follow-up period started from 1 year after diagnosis. The end of follow-up was the earliest date of death, end of registration with the practice, last collection of data from the practice, or last linkage between the CPRD and ONS death records.
Definition of Exposure
We used the British National Formulary to compile a list proprietary and generic medication names for CCBs (eAppendix 1; http://links.lww.com/EDE/B324). We added a lag of 12 months to CCB use as these medications are unlikely to have an immediate effect on breast cancer progression, and to prevent reverse causation. 23, 24 A diagram illustrating our design is shown in eAppendix 2 (http://links.lww.com/EDE/B324). We defined patients as users if they had at least one CCB prescription during the exposure period. Our medication data did not include details on whether the medication was dispensed, or eventually used by the patient. To enable the testing of doseresponse relationships, we extracted data on the medication prescribed, number of packs/tablets and medication strength, and calculated defined daily doses. The defined daily dose system is a validated measure of drug consumption maintained by the World Health Organisation. 25 A single defined daily dose is the average maintenance dose per day of a drug used for its main indication in adults (e.g., hypertension for CCBs). There was insufficient information to calculate defined daily doses for 0.2% of prescriptions, and implausible values were recorded in a further 0.1% (e.g., one tablet; >50,000 tablets). In these cases, we assumed the most common defined daily dose based on other prescriptions with complete information. We calculated a running defined daily dose total for each patient and identified the day when patients received their first (first use), 365th (1 year's use), 1,095th (3 year's use), and 1,825th (5 year's use) defined daily dose.
Covariates
Patients' age, smoking, alcohol, and obesity (body mass index >30) data were determined from the closest general practitioner (GP) record before breast cancer diagnosis (values more than 10 years before diagnoses were ignored). We used GP records to identify prediagnosis comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), using a list of Read codes modified for use in the CPRD, 22 as comorbidities have been consistently associated with higher cancer mortality. 26 Deprivation data were available from census information, and based on the 2010 Index of Multiple Deprivation (IMD) score of the patient's postcode. The NCDR included detailed information about the patient's cancer, including diagnosis year, stage, histologic grade, and treatment (surgery, chemotherapy, and radiotherapy). We used CPRD prescription records to identify patients who received hormone therapy treatment (tamoxifen or aromatase inhibitors), and those who had used oral contraceptives or hormone replacement therapy (HRT) before diagnosis, as these have been shown to influence breast cancer progression previously.
27,28
Statistical Analysis
We calculated descriptive statistics and compared the demographic and clinical characteristics of the CCB users and nonusers, and calculated 1-, 2-, and 5-year cancer-specific survival probabilities. We used time-dependent Cox regression models to calculate hazard ratios (HRs) comparing breast cancer-specific death between CCB users and nonusers. In our primary analysis, we included CCB use as a time-varying covariate to avoid immortal time bias. 29 Therefore, patients were initially included within the analysis as nonusers until 12 months after their first use (due to the exposure lag), after which they were included as users. Our primary analysis adjusted for age at diagnosis, year of diagnosis, deprivation quintile, comorbidities (separate terms for each), prior use of HRT or oral contraceptives, and treatment within 6 months of diagnosis (separate terms for surgery, chemotherapy, radiotherapy, tamoxifen, aromatase inhibitors). Comorbidities were not included as time-varying covariates due to the possibility that changes in health status could lie on the causal pathway between CCB use and breast cancer mortality. We repeated our analysis by number of defined daily doses prescribed (e.g., patients were included in the 1-364 defined daily dose group until 12th months after they received their 365th defined daily dose), and for each commonly prescribed CCB medication (≥2% usage in cohort).
Sensitivity and Subgroup Analyses
We conducted sensitivity analysis for all-cause mortality, and for cause-specific mortality where the definition of breast cancer death was expanded to include secondary causes of death. We also conducted sensitivity analysis with a lag period of zero (patients followed-up from diagnosis), 6 months (patients followed-up from 6 months after diagnosis), and 2 years (patients followed-up from 2 years after diagnosis). We performed two simplified analyses which controlled for immortal time bias without requiring time-varying covariates. 29 First, we based CCB usage on the year after diagnosis, and restricted our analysis to patients living at least 1 year. Second, we based CCB usage on the year before diagnosis, and followed-up patients from the date of diagnosis. Diagrams illustrating the design of our sensitivity analyses which vary the exposure lag and/or period are given in eAppendix 2 (http://links.lww.com/EDE/B324). To facilitate comparison between studies, we repeated our analysis using methods broadly similar to the previous Holmes et al. 17 analysis for all-cause, breast cancer, and cardiovascular (ICD 10 codes: I0-I99, G45, Q20-26, F01) deaths. Specifically, we based CCB usage on the year before breast cancer diagnosis, did not adjust for comorbidities, and restricted the nonuser group to those who did not receive any antihypertensive medication (diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, α-adrenoceptor blocking drugs, β-blockers, angiotensin converting enzyme [ACE] inhibitors, angiotensin II receptor blockers [ARBs], renin inhibitors, and calcium channel blockers) during the exposure period.
To ensure that confounding by indication was not driving our results, we conducted three further sensitivity analysis restricted to patients with similar diagnoses. First, we restricted our analysis to patients with a record of hypertension (Read code categories G20 and 662) in the year before diagnosis. Second, we restricted our analysis to patients who used an antihypertensive medication in the year before breast cancer diagnosis. Third, we compared patients who received CCBs to those who received a different antihypertensive medication after diagnosis (using a time-varying covariate) as the use of an active comparison can overcome several common pharmacoepidemiologic biases. 30 We performed additional sensitivity analysis adjusting for cancer diagnosis details (stage, grade) and patient lifestyle (smoking, alcohol consumption, obesity) using complete case and multiple imputation with chained equations. This imputation used ordered logit models with age, deprivation, death indicator, and the baseline hazard function as covariates. 31 Briefly, multiple imputation with chained equations is a simulation-based approach for handling missing data which leads to valid statistical inferences under certain circumstances. 32 Finally, we conducted a complete case analysis adjusting for cancer diagnosis details (stage, grade), but limited to patients registered with the Northern & Yorkshire Cancer Registry, the registry with the most complete staging information in England (92% of all patients). Restricting our analysis to patients with more complete data could help reduce potential biases due to missing confounder data. Finally, we used the Fine and Gray 33 subdistribution hazard model to assess the impact of competing risks from non-breast cancer deaths.
RESULTS
Cohort Description
There were 54,190 breast cancer cases recorded within the NCDR between 1998 and 2012. We excluded 30,521 patients from the analysis, most commonly because they were diagnosed before they registered with a CPRD practice or before their practice was deemed up to research standard (n = 12,418), they were diagnosed after they left a CPRD practice or data were last collected from it (n = 9,989), they had a record of previous cancer (n = 4,775), or they lived for <12 months after diagnosis (n = 3,189). Therefore, our analysis cohort included 23,669 patients (126,154 person-years), of which 5,141 (21.7%) were CCB users (21,834 person-years). Median follow-up was 5.5 years (maximum 17.8 years). CCB users were more likely to be older, from a deprived area, have comorbidities, be treated with aromatase inhibitors, have lower stage cancer, be non-or ex-smokers, consume no alcohol, and be obese (Table 1) .
Association Between CCB Use and Mortality
Overall, CCB users were at a higher risk of breast cancer death than nonusers (unadjusted HR = 1.13, 95% CI = 1.03, 1.25; Table 2 ). Consequently, cancer-specific survival was slightly lower among CCB users at 1 (0.96 vs. 0.97), 2 (0.93 vs. 0.94), and 5 years (0.86 vs. 0.88) from start of follow-up. However, after adjustment for demographics, comorbidities, treatment, and other medication use, CCB users had a similar risk of breast cancer death (adjusted HR = 0.98, 95% CI = 0.88, 1.08). There was no evidence of a dose-response relationship; we observed small differences in breast cancer death even when comparing nonusers to those who received at least 1,825 defined daily doses (adjusted HR = 0.97, 95% CI = 0.76, 1.24). Similarly, there was no evidence of an association between medication use and breast cancer death for any of the four specific CCBs included in our analysis, with adjusted HRs ranging from 0.95 (95% CI = 0.77, 1.19) for felodipine to 1.05 (95% CI = 0.93, 1.19) for amlodipine ( Table 2 ).
Sensitivity and Subgroup Analyses
Our results were similar in the simpler analysis basing CCB use on the first year after diagnosis (Table 3) . Classifying CCB using the year before diagnosis lead to a slightly higher association (adjusted HR = 1.06, 95% CI = 0.95, 1.19), although this was broadly consistent with our main analysis. CCB users had a much higher risk of all-cause death (unadjusted HR = 1.59, 95% CI = 1.49, 1.69); however, this was substantially attenuated to 1.04 (95% CI = 0.97, 1.11) after adjustment. Our results were robust to changes in the exposure lag period from 0 to 2 years, when expanding our breast cancer-specific death definition to include secondary causes, when accounting for competing causes of death, and did not change appreciably when adjusting for cancer diagnosis (i.e. stage, grade) or patient lifestyle factors using complete case or multiple imputation methods. We observed broadly similar hazard ratios when restricting our analysis to patients with a prior diagnosis of hypertension (0.89; 95% CI = 0.71, 1.12), to those in receipt of antihypertensive medications before diagnosis (0.95; 95% CI = Adjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), and other medication use (prior use of hormone replacement therapy, oral contraceptives).
CI indicates confidence interval; DDD defined daily dose.
0.84, 1.07), or when comparing CCB users to patients receiving a different antihypertensive medication after breast cancer diagnosis (1.02; 95% CI = 0.92, 1.13). When repeating the analysis using similar methods to Holmes et al., 17 we found substantially higher all-cause mortality among CCB users (HR = 1.27; 95% CI = 1.17, 1.38), but this largely reflected cardiovascular (HR = 2.22; 95% CI = 1.81, 2.72) rather than breast cancer (HR = 1.11; 95% CI = 0.98, 1.25) deaths.
DISCUSSION
Summary of Main Findings
In this large, population-based cohort of newly diagnosed breast cancer patients, we did not observe any evidence of an increase in breast cancer-specific mortality with CCB use after adjustment for patient demographics, comorbidities, and other medication use. There was no evidence of a doseresponse relationship. We found similar associations for specific CCBs and for all-cause mortality.
Strengths and Weaknesses
Our study is the first to investigate postdiagnosis CCB use and breast cancer-specific mortality. It is based on a highquality population-based cohort of patients with registryconfirmed breast cancer, 18 and is more than five times larger than the previous study. 17 Patients included in the study had a long follow-up period after diagnosis of up to 17 years, which should allow any clinically important effect of CCBs on breast cancer progression to become apparent. Linkage to ONS death registration data allowed robust verification of death, and facilitated a breast cancer-specific analysis, which should be more sensitive to small changes in disease-specific mortality, and less susceptible to confounding by indication than all-cause deaths. 24, 34 Although some misclassification of death cause is possible, studies have shown this is likely to have a limited impact on our estimates (as there is no obvious mechanism for differential misclassification) 35 and our results were similar when expanding our breast cancer death definition to include secondary causes.
We used prescribing data collected as part of routine clinical care which accurately reflects GP prescribing practices and negates the risk of recall bias. These data also included detailed information on the type of CCB, and the strength, quantity, and timing of prescription, which allowed us to investigate dose-response relationships, and conduct separate analysis for specific medications. CCBs are not available over the counter in the United Kingdom, which negates exposure misclassification due to over-the-counter usage.
Our study has several potential weaknesses. It is observational and hence open to confounding. Although we have adjusted for several of the key determinants of breast cancer progression (e.g., age, comorbidities and treatment), some risk factors, including ethnicity and nutrition, were not available within our dataset. 36, 37 Other important prognostic variables such as cancer stage and grade were incomplete, and so omitted from our primary analysis. The reason stage was not available for a high proportion of breast cancer patients within the NCDR is unclear, although similar patterns have been reported elsewhere. 38 Nevertheless, the findings from our sensitivity analyses suggest that confounding or missing data issues were not solely driving our results. For example, our conclusions were unchanged when using multiple imputation to adjust for cancer stage and grade, or restricting our analysis to a single registry with almost complete staging data. Moreover, we observed little evidence of an association when using other antihypertensive medications as an active comparator (which should be confounded in a similar way to CCBs). The proportion of patients receiving surgery is slightly lower than reported in note reviews from Northern Ireland (which has a similar healthcare system to England), 39 suggesting that some misclassification of cancer treatment is possible.
Last, we do not know if patients adhered to their prescribed medications, but our main conclusions were similar when restricting our analysis to patients who received multiple prescriptions (>1,825 daily defined doses), where noncompliance is less of a concern.
Comparison with Previous Studies
We are unaware of any other studies that have compared breast cancer-specific mortality between CCB users and Except for "CCB versus other antihypertensive medication" where patients who received a different antihypertensive medication serve as the reference group. b Adjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), and other medication use (prior use of hormone replacement therapy, oral contraceptives).
nonusers. One recent cohort study of 4,019 Canadian patients with registry-confirmed breast cancer by Holmes et al. 17 reported a 22% (HR = 1.22; 95% CI = 1.02, 1.47) increase in all-cause mortality among CCB users. However, this study did not examine postdiagnostic mediation use, did not investigate cancerspecific mortality, could not adjust for comorbidities, restricted their nonuser group to patients not receiving antihypertensive medications, and had much shorter follow-up (maximum of 6 years) than our study. We found a comparable increase of 27% (HR = 1.27; 95% CI = 1.17, 1.38) in our cohort when using similar methods to those employed by Holmes et al., 17 which was largely driven by cardiovascular deaths (HR = 2.22; 95% CI = 1.81, 2.72), suggesting that their estimates may have been substantially inflated by these potential weaknesses.
CONCLUSIONS
CCBs are a widely used and effective treatment for cardiovascular conditions such as hypertension and angina. Although concerns have persisted that their use may lead to malignant growth through increased apoptotic evasion and cancer cell proliferation, [11] [12] [13] our large, population-based cohort study did not find any evidence that CCB use is associated with increased breast cancer mortality.
